Innovative approaches to treatment - refractory depression: The ketamine story

[6],[7] For example, antagonists of the NR2B subtype of the NMDA receptor are currently under development as potential antidepressant treatments; and traxoprodil, an NR2B antagonist, has demonstrated antidepressant effects in selective serotonin reuptake inhibitor (SSRI)-resistant patients. [...] in...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of psychiatry 2010-04, Vol.52 (2), p.97-99
Main Authors: Rao, T S Sathyanarayana, Andrade, Chittaranjan
Format: Article
Language:English
Subjects:
Anesthesia
Antidepressants
Binding sites
Blood pressure
Brain-derived neurotrophic factor
Clinical trials
Depression, Mental
Drug therapy
Health aspects
Ketamine
Neurosciences
Serotonin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[6],[7] For example, antagonists of the NR2B subtype of the NMDA receptor are currently under development as potential antidepressant treatments; and traxoprodil, an NR2B antagonist, has demonstrated antidepressant effects in selective serotonin reuptake inhibitor (SSRI)-resistant patients. [...] in an open-label clinical trial of ketamine vs. propofol anesthesia in 31 medication-resistant depressed inpatients referred for ECT, Okamoto et al. [...] the expression of brain-derived neurotrophic factor (BDNF) triggers the neuroplastic changes that hypothetically represent the final common pathway of antidepressant action.
ISSN:0019-5545
1998-3794
DOI:10.4103/0019-5545.64573